You are here: Industry Insights > ViiV

News List

Collaboration to develop ultra-long acting medicines for HIV europeanpharmaceuticalreview
June 23, 2021
ViiV Healthcare is licencing Halozyme’s Enhanze® drug delivery technology to help develop ultra-long acting versions of its long-acting HIV pipeline products.
ViiV Healthcare starts rolling submission of cabotegravir for HIV prevention pharmaceutical-technology
May 06, 2021
ViiV Healthcare has begun a rolling submission of a new drug application (NDA) with the US Food and Drug Administration (FDA) for its long-acting cabotegravir to prevent human immunodeficiency virus (HIV) or pre-exposure prophylaxis (PrEP).
Maturation inhibitor shown to be safe and effective in Phase II HIV trial europeanpharmaceuticalreview
March 12, 2021
The highest doses of the novel maturation inhibitor, GSK3640254, had the greatest antiviral activity and were shown to be safe in 34 treatment-naïve adults with HIV.
Sales of injectable anti-HIV therapeutics will reach $2 billion in 2029: GlobalData expresspharma
March 01, 2021
Cabotegravir-based therapies are projected to generate 79 per cent of the sales of injectable therapeutics in the HIV market in 2029.
ViiV’s Rukobia receives marketing authorisation in Europe for HIV treatment pharmaceutical-technology
February 10, 2021
GlaxoSmithKline’s (GSK) ViiV Healthcare has announced the European Marketing Authorisation of its Rukobia (fostemsavir) 600mg extended-release tablets for use in combination with antiretroviral (ARV) therapies for treating adults with ...
US green light for long-acting HIV regimen Cabenuva pharmatimes
January 25, 2021
The US Food and Drug Administration (FDA) has approved ViiV Healthcare and Janssen’s long-acting regimen for HIV-1 infection Cabenuva (cabotegravir, rilpivirine).
ViiV Healthcare continues HIV care partnership with Chelsea and Westminster Hospital pharmatimes
January 19, 2021
ViiV Healthcare, a GlaxoSmithKline company, is continuing a partnership with Chelsea and Westminster Hospital NHS Foundation Trust to ‘transform’ HIV patient care with digital technology.
ViiV posts positive long-term data for two-drug HIV regimen Dovato pharmatimes
October 14, 2020
GlaxoSmithKline subsidiary ViiV Healthcare has reported new data for its two-drug HIV regimen Dovato, with hopes that the long-term data could encourage clinicians to switch from other triple regimen therapies.
Final data on ViiV's cabotegravir show impressive HIV PrEP pharmatimes
July 09, 2020
ViiV's investigational, long-acting injectable cabotegravir was found to be 66% more effective than daily pills in preventing HIV-1 acquisition, according to final analysis of data from the HPTN 083 study.
ViiV Healthcare seeks EMA approval for HIV-1 drug candidate fostemsavir pharmaceutical-business-review
January 15, 2020
ViiV Healthcare has completed a regulatory filing in Europe seeking the approval for fostemsavir for the treatment of HIV-1 infection in adult patients having limited treatment options.

Previous page 1 2 3 Next page